TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDM
ABBOTT MEDICAL · Decision date Sep 4, 2026
What did the FDA approve?
FDA posted a Panel Track supplement for the TactiFlex Duo Ablation Catheter, Sensor Enabled, listing the reason as change to design, components, specifications, or material. The posted statement repeats the device indication for cardiac electrophysiological mapping and ablation in drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used with a compatible radiofrequency or pulsed field generator and three-dimensional mapping system.
The record does not state which design, component, specification, or material was changed. It also does not state whether the supplement altered the indication or whether the posted statement reflects the original or revised labeling. The supplement is tied to PMA P220013, but the database fields do not describe the relationship between this supplement and the original approval beyond the identifier.
FDA approval order statement
The TactiFlex Duo Ablation Catheter, Sensor Enabled is indicated for use in The TactiFlex Duo Ablation Catheter, Sensor Enabled is indicated for use in cardiac electrophysiological mapping and ablation for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible radiofrequency (RF) or pulsed field (PF) generator and three-dimensional mapping system.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 4, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220013/S028
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- OAE
- Decision code
- APPR
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Abbott Medical
- Product code
- OAE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220013 · Original PMA
TactiFlex Ablation Catheter, Sensor Enabled, TactiSys Quartz Equipment, TactiSys Quartz, TactiFlex Radiofrequency C
P220013/S028 received
Application receipt date recorded by FDA.
P220013/S028 · FDA decision
Panel Track
P220013/S034 · Related supplement
TactiFlex Ablation Catheter, Sensor Enabled
Timeline entries are records held by MedtechLedger for P220013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | May 18, 2023 | FDA | |
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
QDOT MICRO SystemP210027 | Biosense Webster, Inc. | PMA approval | Nov 23, 2022 | FDA |
| Medtronic Cryocath, LP | PMA approval | Dec 17, 2010 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 5050 Nathan Ln. N., Plymouth, MN, 55442
Sources and methodology
- Original FDA record: P220013/S028
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


